Fig. 1

Patient disposition from the final analysis of the GOYA trial. ^aOverall, 1418 patients were randomized (G-CHOP arm: N = 706 and R-CHOP arm: N = 712) to the study; however, due to a serious Good Clinical Practice non-compliance at a single site, data from all 4 patients enrolled at the site (two patients in each arm) were excluded from the final analysis. ^bA patient was considered to have completed the treatment if they received all 8 cycles of study treatment. ^cThe end of the study was defined as the last patient’s last visit and occurred at approximately 6.5 years (78 months) after the first patient was enrolled to allow all patients to have ≥ 3 years of follow-up post-treatment. G-CHOP, obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone